Developing and validating a humanized MISTRG6 mouse model that accurately replicates human immune responses to gluten for celiac disease research and drug development.
Using DIPS, a non-invasive skin sampling technique, to build cytokine-based biomarker panels that predict biologic treatment response in psoriasis and atopic dermatitis.
Investigating how copper transport via SLC31A1 regulates pro-inflammatory Th17 cell activity, this project uncovers a novel link between immune cell metabolism and MS, pointing toward new therapeutic targets.
Engineering HLA-DQ–specific CAR Tregs to selectively suppress anti-donor immune responses at sites of graft inflammation, this project seeks a more precise, durable alternative to broad immunosuppression in transplantation.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Mapping the full antigenic landscape of Sjögren's disease using T-Scan technology to identify the drivers of autoimmune T cell responses and enable targeted therapies.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Modernizing anti-nuclear antibody testing by combining AI-enhanced image analysis with multiplex autoantibody profiling to improve diagnostic precision and uncover novel autoimmune biomarkers.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Investigating the autoimmune and immune dysregulation mechanisms underlying Long COVID to improve diagnosis, treatment, and biological understanding of persistent symptoms.
